Smith & Nephew SNATS, Inc. (NYSE:SNN) Given Consensus Rating of “Hold” by Analysts

Shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) have been assigned a consensus recommendation of “Hold” from the six analysts that are presently covering the company, Marketbeat.com reports. Five research analysts have rated the stock with a hold recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $36.25.

SNN has been the subject of a number of recent analyst reports. Kepler Capital Markets raised Smith & Nephew SNATS to a “strong-buy” rating in a report on Monday, November 17th. Wall Street Zen cut shares of Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. Weiss Ratings restated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a report on Wednesday, January 21st. Royal Bank Of Canada lowered shares of Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a research note on Monday, December 15th. Finally, Canaccord Genuity Group lifted their target price on shares of Smith & Nephew SNATS from $34.00 to $35.00 and gave the stock a “hold” rating in a report on Thursday.

Institutional Trading of Smith & Nephew SNATS

Large investors have recently added to or reduced their stakes in the business. River Road Asset Management LLC lifted its holdings in Smith & Nephew SNATS by 13.8% during the fourth quarter. River Road Asset Management LLC now owns 3,169,644 shares of the medical equipment provider’s stock valued at $103,996,000 after purchasing an additional 384,926 shares in the last quarter. NewEdge Advisors LLC lifted its stake in shares of Smith & Nephew SNATS by 18.7% during the 4th quarter. NewEdge Advisors LLC now owns 7,571 shares of the medical equipment provider’s stock valued at $248,000 after buying an additional 1,192 shares in the last quarter. XTX Topco Ltd boosted its holdings in Smith & Nephew SNATS by 165.1% in the 4th quarter. XTX Topco Ltd now owns 49,063 shares of the medical equipment provider’s stock worth $1,610,000 after buying an additional 30,553 shares during the period. Voloridge Investment Management LLC bought a new stake in Smith & Nephew SNATS during the fourth quarter valued at about $330,000. Finally, OLD Mission Capital LLC purchased a new position in shares of Smith & Nephew SNATS in the fourth quarter valued at about $7,438,000. 25.64% of the stock is currently owned by institutional investors.

Smith & Nephew SNATS Price Performance

SNN opened at $34.86 on Friday. The company’s 50-day moving average price is $34.40 and its two-hundred day moving average price is $34.95. Smith & Nephew SNATS has a twelve month low of $23.91 and a twelve month high of $38.79. The company has a current ratio of 2.57, a quick ratio of 1.40 and a debt-to-equity ratio of 0.60.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.